Why the Opthea share price has rocketed 450% higher this year

The Opthea Ltd (ASX:OPT) share price has been on fire in 2019. Here's why….

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

One of the best performers on the All Ordinaries index this year has been the Opthea Ltd (ASX: OPT) share price.

Since the start of the year the shares of the developer of novel biologic therapies for the treatment of eye diseases have rallied over 450% higher.

To put that into context, a $20,000 investment on January 1 would now be worth $110,000.

Why is the Opthea share price up 450% in 2019?

Investors have been buying Opthea's shares in a hurry this year following the success of a study related to its OPT-302 combination therapy for treatment-naïve patients with wet age-related macular degeneration (AMD).

According to the study update, the OPT-302 (2.0 mg) combination therapy showed statistical superiority for the most accepted and sensitive primary efficacy outcome.

This has the potential to be a major positive for the company. This is because the current standard of care treatments for wet AMD had sales of US$3.7 billion in 2018.

Furthermore, there is potential for the therapy to be used for Diabetic Macular Edema (DME) as well. The current standard of care for DME generated sales of US$6.2 billion in 2018.

Combined, the OPT-302 combination therapy has a ~US$10 billion market opportunity. In light of this, I can't say I'm surprised to see its shares race higher this year.

What else has driven its shares higher?

One broker that is especially bullish on the company is Goldman Sachs. Following the study update, the broker added Opthea to its conviction list with a buy rating and $4.90 price target.

This price target implies potential upside of over 40% for its shares, even after 2019's stellar gains.

Goldman Sachs believes that "OPT-302 has multi-billion dollar potential."

Its analysts said: "As successful as current treatments have been, they only inhibit up to two of the factors responsible for the disease (VEGF-A/B). Over half of patients do not achieve significant vision gains, and a quarter experience continued vision loss. OPT-302 is intended for use in combination with these treatments, blocking a further two factors (VEGF-C/D), hence targeting improved outcomes via a more complete blockade."

In light of this, it has suggested that in the future it could achieve "non-risk-adjusted peak sales of US$5.0bn (US$2.0bn risk-adjusted), of which US$3.4bn relates to wAMD (US$1.7bn)."

I think Goldman makes some great points and Opthea could be well worth considering. Though, it is a high risk investment at this stage.

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has recommended ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Gainers

Stock market chart in green with a rising arrow symbolising a rising share price.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a massive day for the ASX 200, with a new all-time high recorded.

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Technology Shares

This ASX tech stock rocketed 60% in March! Can it keep on delivering?

After soaring in March, the ASX tech stock is now up 169% since this time last year.

Read more »

A young women pumps her fists in excitement after seeing some good news on her laptop.
Share Gainers

Why Mesoblast, Newmont, Pilbara Minerals, and Platinum shares are jumping

These ASX shares are ending the week strongly. But why?

Read more »

A young male ASX investor raises his clenched fists in excitement because of rising ASX share prices today
Share Gainers

3 ASX All Ords shares up 50%+ in March

These ASX shares have been on fire this month. But why?

Read more »

Woman looks amazed and shocked as she looks at her laptop.
Share Gainers

Why Mesoblast, Patriot Battery Metals, Sigma, and Zip shares are pushing higher

These shares are having a good session on hump day. But why?

Read more »

Woman looks amazed and shocked as she looks at her laptop.
Consumer Staples & Discretionary Shares

If you'd put $20,000 in this ASX retail stock at the start of 2023, you'd have $134,000 now

This online retailer has executed a remarkable turnaround for its investors.

Read more »

Fancy font saying top ten surrounded by gold leaf set against a dark background of glittering stars.
Share Gainers

Here are the top 10 ASX 200 shares today

It was back to earth for ASX shares this Tuesday.

Read more »

Two happy scientists analysing test results.
Healthcare Shares

Mesoblast share price rockets 36% on breaking FDA news

ASX investors are sending the Mesoblast share price soaring following promising FDA news.

Read more »